reinhard angelmar the salmon and rameau fellow in healthcare management professor of marketing...
TRANSCRIPT
![Page 1: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/1.jpg)
Reinhard AngelmarThe Salmon and Rameau Fellow in Healthcare Management
Professor of MarketingINSEAD, Fontainebleau, France
The International Pharmaceutical Regulatory and Compliance Congress June 6-7, 2007
Sheraton Brussels Hotel and Towers, Brussels, Belgium
INDUSTRY IMAGE AND TRUST FROM A EUROPEAN PERSPECTIVE
![Page 2: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/2.jpg)
2
INTERNET ASSOCIATIONS
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
1800000
and "unethical" and "evil"
"Pharmaceutical companies" "Tobacco companies"
"Oil companies" Mystery benchmark
Google Search, May 8, 2007
![Page 3: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/3.jpg)
3
Strong Industry Brand equity
INDUSTRY BRAND EQUITY
• Seek, pay for, and adhere to medical treatment
• Political support for industry
• Prescribe medicines
• Political support for industry
• Industry-friendly policies
• Favor medical treatment and pay fair prices for medicines
• Political support for industry
• Supportive of industry
• Positive coverage of industry
• Political support for industry
High industry awareness
Strong, favorable,
unique associations
Benefits of a Strong Industry Brand Equity
Consumers (voters)
Physicians/ HC
profess.
Policy makers
Payers
Media
NGOs
![Page 4: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/4.jpg)
4
COUNTRY HEALTH EXPENDITURE(% of GDP)
![Page 5: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/5.jpg)
5
HEALTH EXPENDITURE FINANCING: 2004
![Page 6: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/6.jpg)
6
CHANGE IN SHARE OF PUBLIC SPENDING ON HEALTH: 1990 – 2004(ranked by 1990 public share)
![Page 7: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/7.jpg)
7
Age-related change in public expenditure: EU15 - 2004-2050 (% of GDP)
Source: The impact of aging on public expenditure. Projections for the EU25 Member States,Report of the DG ECFIN, 2006
![Page 8: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/8.jpg)
8
Source: Eurobarometer, Feb 2007
Fieldwork: Nov-Dec 2006
Source: Eurobarometer, European Social Reality, February 07
ISSUES OF CONCERN FOR EUROPEANS: EU25
![Page 9: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/9.jpg)
9
DRUG SPENDING AS PERCENT OF TOTAL HEALTH SPENDING, 2004
38.5
29.6
27.6
27.4
24.8
23.1
22.8
22.0
21.1
20.9
18.9
18.9
17.7
17.7
17.4
16.3
14.8
14.1
13.0
13.0
12.8
12.4
12.3
12.3
11.5
11.3
10.4
9.5
9.4
8.5
0
5
10
15
20
25
30
35
40
45
Slo
vak
Rep
ub
lic
(3)
Po
lan
d
Hu
ng
ary
Ko
rea
Tu
rkey
(1)
Po
rtu
gal
Sp
ain
Cze
ch R
epu
bli
c (2
)
Ital
y
Mex
ico
Fra
nce
Jap
an (
3)
Can
ada
OE
CD
Gre
ece
Fin
lan
d
Icel
and
(2)
Ger
man
y
Au
stri
a
Un
ited
Kin
gd
om
(4)
Au
stra
lia
Irel
and
Sw
eden
Un
ited
Sta
tes
Net
her
lan
ds
(2)
Bel
giu
m (
3)
Sw
itze
rlan
d
No
rway
Den
mar
k
Lu
xem
bo
urg
(1): 2000; (2): 2002); (3): 2003; (4) OFT estimate. Source: OECD Health Data 2006
![Page 10: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/10.jpg)
10
ANNUAL GROWTH IN EXPENDITURES (1998-2003): Total Health and Pharmaceuticals
![Page 11: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/11.jpg)
11
MAIN HEALTHCARE EXPENDITURE COMPONENTSCountries ranked by total share of in-patient care of current expenditure on health
![Page 12: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/12.jpg)
12
SELECTED STAKEHOLDERS
Pharma-cies
Physicians
Other service
providers(comple-mentors)
THIRD-PARTY
PAYERS: Public / Private
Em-ployers
Consumers (Patients) /
Employees / Taxpayers
PHARMA COS
Mktg Authorization Agency (e.g.,
EMEA)
Product / Service Flow
Financial / Payment Flow
Price approval
authorities(e.g.,
Ministry)
HEALTH TECHNOLOGY ASSESSMENT
CENTERS
![Page 13: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/13.jpg)
13
THE POWER GAME
• Change in relative power– Traditionally strong stakeholders become less
powerful– Traditionally disempowered stakeholders become
more powerful
• Pharmaceutical industry’s relative power declines
• Zero-sum game perception heightens conflict between health care sector players
• Conflict is resolved in favor of players that– are more powerful– have stronger brand equity
![Page 14: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/14.jpg)
14
COMPONENTS OF INDUSTRY BRAND EQUITY
R&D / Innovation
Safety of
Medicines Pricing
Sales &
Marketing
Valueof
medicines
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
ENGAGEMENT WITH STAKEHOLDERS
TRANSPARENCY
TRUST
• Patient outcomes
• Healthcare cost impact
• Aggressive-ness
• Ethics
• Price level of medicines
• Access to medicines
• Industry profitability
In
• Development
• Regulatory
• Post-launch
• Choice of disease areas
• R&D costs (vs marketing costs)
• Industry’s role in innovation
OVERALL ATTITUDE TOWARD INDUSTRY (FAVORABILITY)
![Page 15: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/15.jpg)
15
DETERMINANTS OF TRUSTHIGH CAPABILITY - COMPETENT
LOW CAPABILITY - INCOMPETENT
ALTRUISTIC MOTIVESSELFISH MOTIVES
![Page 16: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/16.jpg)
16
SURVEY RESULTS
![Page 17: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/17.jpg)
17
Perception gaps• between beliefs and reality
• between beliefs of different stakeholders
![Page 18: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/18.jpg)
18
PERCEPTION GAPS: USConsumer estimates of cost to bring average drug
to market (percent of respondents)Percent agreement that drug companies make drug development decisions based on ‘unmet
need’
Percent agreement that drug companies have sufficient programs in place to monitor their products’ post-market
safety profile and public health risks
Percent agreement that drug companies need to improve transparaency in reporting clinical trial results
![Page 19: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/19.jpg)
19
PERCEPTION GAPS: US (cont’d)Percent agreement that drug companies spend to much
on drug promotion
Percent agreement that DTC advertising provides complete and useful information to consumers
Percent agreement that drug companies can be too aggressive in promoting unapproved uses of their products
Consumer estimates of the amount of overall U.S. healthcare spending comprised by prescription drug costs
![Page 20: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/20.jpg)
20
PERCEPTION GAP: Credit for the discovery of new medicines, EU survey
11
11
15
23
41
0 5 10 15 20 25 30 35 40 45
The PharmaceuticalIndustry
Doctors
Local or NationalGovernment
Hospitals andMedical Schools
Other MedicalProfessionals
11
11
15
23
41
0 5 10 15 20 25 30 35 40 45
The PharmaceuticalIndustry
Doctors
Local or NationalGovernment
Hospitals andMedical Schools
Other MedicalProfessionals
“If you had 10 units of credit for the discovery of new medicines, how many of those 20 units would you assign to each of the following:”
Source: Pfizer, 2004
![Page 21: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/21.jpg)
21
PERCEPTION GAP: Pharmaceuticals in % of total HC costs
Average38
%
18
13
22
20
16
11
0 5 10 15 20 25
More Than 50%
50%
40%
30%
20%
10% or Less
18
13
22
20
16
11
0 5 10 15 20 25
More Than 50%
50%
40%
30%
20%
10% or Less
Percent of Health Care Cost
Survey average: 38%Source: Pfizer, 2004
OECD Average: 18%
![Page 22: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/22.jpg)
22
OVERALL ATTITUDE TOWARD THE INDUSTRY
![Page 23: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/23.jpg)
23
ATTITUDE TOWARD INDUSTRY: EU Elites1% 1%
3%
7%
18%
17%
24%
21%
4%
2%3%
1%
4%
6%
14%
14%
28%
19%
6%
4%4%
6%
27%
18% 20
%
20%
5%
1%2% 1%
3%
8%
16% 18
%
25%
23%
3% 2%
1 2 3 4 5 6 7 8 9 10
TOTAL (Mean = 6.35)
NGO (Mean = 6.45)
Media (Mean = 6.29)
Gov't (Mean = 6.33)
Extremely Unfavorable Extremely
Favorable
“How do you rate your overall feelings toward the pharmaceutical industry? Please use a scale from one to ten, where one means you feel “extremely unfavourable” and ten means you feel “extremely favourable” toward the industry.”
Source: APCO/EFPIA, 2005
EU Policymakers (n=147): EU Parliament, Commission, Council Permanent RepresentativesNGOs (n=80): international organizations, think tanks, trade and professional associaitons,
health NGOs, patient organizationsMedia (n=88): Pan-European and key national specialized and non-specialized media
![Page 24: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/24.jpg)
24
How favourable or unfavourable is your overall opinion or impression of the Pharmaceutical Industry?
ATTITUDE TOWARD INDUSTRY: UK MPs
0
20
40
60
80
100
Favourable Unfavourable
Base: All MPs asked, Summer 1996 – Summer 2006
16%
General Election
67%
% Favourable/
UnfavourableGeneral Election General
Election
Source: MORI / ABPI, 2006
![Page 25: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/25.jpg)
25
ATTITUDE TOWARD INDUSTRY: UK MPs
42%39%39%38%
36%36%
32%31%
29%27%
19%19%
11%
6%16%15%
9%13%
29%12%
22%38%
28%18%
20%36%
19%36%
32%39%
46%65%
44%46%
53%54%
67%68%Biotechnology
Favorable
PharmaceuticalsOil exploration and production
AgricultureEnergy
Unfavorable
Nuclear energyChemicals
Base: All MPs
GasSupermarkets
Nuclear Decommissioning and clean up
ConstructionPetrol
BankingAccountancy
Mobile phone operatorsDebit cards
PensionsWater services
Credit cards
Source: MORI / ABPI, 2006
![Page 26: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/26.jpg)
26
For each of the following industries, please rate your overall opinion or impression of them, according to the scale shown - Pharmaceutical companies
DECEMBER (1) 2006OPINIONS OF CERTAIN INDUSTRIES
ATTITUDE TOWARD INDUSTRY: UK GPs
7%
35%33%
21%
6%
Very unfavourable(1)
Slightly unfavourable(2)
Neither favourablenor unfavourable (3)
Slightly favourable(4)
Very favourable (5)
Base: All respondents (200)
Mean Score = 3.2
Source: GfK / ABPI, December 2006
![Page 27: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/27.jpg)
27
For each of the following industries, please rate your overall opinion or impression of them, according to the scale shown
DECEMBER (1) 2006OPINIONS OF CERTAIN INDUSTRIES
ATTITUDE TOWARD INDUSTRY: UK GPs
3
3.6
1.4
2.7
2.6
3
3.1
2.9
2.8
3.2 Pharmaceutical companies
Banking
Chemicals
Food
Car
Oil & petrol
Rail
Tobacco
NHS
Local PCT/ SHA
Base: All respondents (200)
MEAN SCORE
Source: GfK / ABPI, December 2006
![Page 28: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/28.jpg)
28
ATTITUDE TOWARD INDUSTRY: UK General Public
How favourable or unfavourable is your overall opinion or impression of the pharmaceutical industry?
Base: General Public 1991-2006
0
10
20
30
40
50
60
1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Favourable Unfavourable%
Year
14%
51%
Source: MORI / ABPI, 2006
![Page 29: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/29.jpg)
29
REASONS FOR POSITIVE orNEGATIVE ATTITUDES
![Page 30: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/30.jpg)
30
-1.5
-1
-0.5
0
0.5
1
1.5
1.0 1.5 2.0 2.5 3.0
Mean Favourability
Mean Familiarity
Familiarity and Favourability – General public
Base: All respondents (1,997), Summer 2006
Banking
FoodPharmaceuticals
Chemicals
Oil & petrol
Car
Rail
Tobacco
![Page 31: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/31.jpg)
31
INDUSTRY POSITIVES: EU Elites
Percent of Respondents
49%
38%
4%
4%
3%
3%
8%
1%
0% 10% 20% 30% 40% 50% 60%
THERAPEUTIC BENEFITS/CURESILLNESSES/SAVES LIVES
R&D/INNOVATION
QUALITY OF PRODUCTS
GENERALLY CONTRIBUTES TO SOCIETY
WEALTH CREATION AND EMPLOYMENT
PHILANTHROPY
OTHER
NOT SURE
On the question of the pharmaceutical industry, people often express both favourable and unfavourable impressions. On the positive side, what is the
main reason that people might regard the pharmaceutical industry favourably?
Source: APCO/EFPIA, 2005
![Page 32: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/32.jpg)
32
INDUSTRY POSITIVES: UK GPs
9%
6%
5%
6%
7%
7%
7%
7%
12%
12%
15%
27%
32% Produce/ develop new/ valuable/ good products
(Spend a lot/ good in) research and development
But still profit motivated
But dislike some of their marketing practices
Doing an important/ good job/ service
Sponsor/ help with education
Necessary industry
Are generally ethical/ adhere to a code of practice
Help/ support us/ our profession
Like/ respect/ knowledgeable representatives
Efficient/ well organised/ have good procedures (unspec)
Other
Don't know
“Why do you say that you have a slightly/very favourable opinion of the pharmaceuticals industry?”
Base: All who have a slightly or very favourable opinion of the pharmaceutical industry (82)
DECEMBER (1) 2006OPINIONS OF CERTAIN INDUSTRIES
Source: GfK / ABPI, December 2006
![Page 33: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/33.jpg)
33
INDUSTRY NEGATIVES: EU Elites
48%
11%
10%
9%
7%
5%
5%
4%
3%
2%
17%
1%
0% 10% 20% 30% 40% 50% 60%
PRICES TOO HIGH/EMPHASIS ON PROFITS RATHER THANHEALTHCARE
MARKETING STRATEGIES/EXAGGERATES BENEFITS
ATTITUDE TOWARDS/LACK OF R&D FOR 3RD WORLD/POOR
UNETHICAL/IGNORES OR HIDE SIDE EFFECTS
ABUSE OF MONOPOLY POSITION/INTELLECTUAL PROPERTY
DENIES ACCESS TO 3RD WORLD/RESTRICTIONS ON IMPORTING
LACK OF TRANSPARENCY - GENERAL
LACK OF TRANSPARENCY - TRIAL RESULTS
ANIMAL TESTING
LACK OF HEALTHCARE KNOWLEDGE/DRUG SAFETY
OTHER
NOT SURE
On the negative side, what is the main reason that people might regard the pharmaceutical industry unfavourably?
Source: APCO/EFPIA, 2005
![Page 34: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/34.jpg)
34
INDUSTRY NEGATIVES: UK GPs
2%
4%
4%
4%
4%
8%
8%
8%
10%
13%
15%
33%
46% Profit motivated/ large profits/ profit
before patient Biased/ misleading/ not enough
information/ research Dislike
marketing/ advertising/ promotions Corruptive/ unethical/ underhand/ do
not trust them Pushing expensive/ unnecessary
drugs
Too many \ me too\ " drugs"
Representatives areslimey/ pushy/ untrustworthy
Expensive/ will not reduce prices
Dislike patent extension
Third world disease creation
Have/ set their own agenda
Other
Don't know
“Why do you say that you have a slightly/very unfavourable opinion of the pharmaceuticals industry?”
Base: All who have a slightly or very unfavourable opinion of the pharmaceutical industry (52)
DECEMBER (1) 2006OPINIONS OF CERTAIN INDUSTRIES
Source: GfK / ABPI, December 2006
![Page 35: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/35.jpg)
35
InnovationPricing Transparent Communication
Philanthropy
Health OutcomesSafety
Engagement
Profitability
Source: APCO/EFPIA, 2005
REPUTATION IMPACT and INDUSTRY PERFORMANCE: EU Elites
![Page 36: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/36.jpg)
36
Stakeholder Divergences: EU Elites
InnovationPricing
TransparentCommunication
PhilanthropyHealth Outcomes
Safety
Engagement Profitability
InnovationPricing
Transparent Communication
Philanthropy
Health OutcomesSafety
Engagement
Profitability
NGOMediaGovernment
Innovation
Pricing
Transparent Communication
Philanthropy
Health Outcomes
Safety
Engagement
Profitability
Source: APCO/EFPIA, 2005
![Page 37: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/37.jpg)
37
TRUST IN INDUSTRY
![Page 38: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/38.jpg)
38
TRUST IN INDUSTRY: US Adults
Source: HarrisInteractive. Online survey: 2,010 U.S. adults, October 4-10, 2006
2003 2004 2005 2006
% % % % Supermarkets 40 42 39 34 Banks 35 40 34 31 Hospitals 34 35 34 28 Computer software companies 22 25 22 23 Computer hardware companies 27 29 27 20 Airlines 20 22 17 16 Packaged food companies 23 23 21 14 Electric and gas utilities n/a n/a 14 14 Online retailers n/a n/a 16 11 Life insurance companies 11 15 10 11 Telephone companies 12 13 11 10 Car manufacturers 14 18 13 9 Pharmaceutical and drug companies 13 14 9 7 Health insurance companies 7 9 9 7 Managed care companies such as HMOs
4 5 5 4
Oil Companies 4 4 3 3 Tobacco companies 3 4 4 2 None of these 37 32 37 40
"Which of these industries do you think are generally honest and trustworthy – so that you normally believe a statement by a company in that industry?"
![Page 39: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/39.jpg)
39
76%79%
76%73% 73%
76%
23%20% 22%
26% 27%24%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
2002 2003 2004 2005 2006 2007
Trust No trust
TRUST IN INDUSTRY:France – General Public
Source: IFOP/Leem, 2007
« Faites-vous tout à fait confiance, plutôt confiance, plutôt pas confiance ou pas du tout confiance aux Entreprises du Médicament? »
![Page 40: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/40.jpg)
40
TRUST IN INDUSTRY:Physicians in 5 countries
Agreement with « trustworthy »as a descriptor of the pharmaceutical industry
Source: Harris Interactive, 2004
![Page 41: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/41.jpg)
41
NUMBER OF TRUSTED SALES REPS: GPs in Germany
Source: INSEAD Survey, 2007
![Page 42: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/42.jpg)
42
TRUST IN INDUSTRY INFORMATION – CREDIBILITY AS A SOURCE OF INFORMATION ABOUT HEALTHCARE: EU
%
University medical centers 51
National association of doctors 40
New healthcare alliance/doctors, pharma companies, pharmacists, patient groups 35
Patient advocacy organizations 35
National association of pharmacists 31
National association of pharmaceutical
research and manufacturing companies 26
Government agency 21
Leading pharmaceutical company like
Merck, Pfizer or Novartis 14
%
University medical centers 51
National association of doctors 40
New healthcare alliance/doctors, pharma companies, pharmacists, patient groups 35
Patient advocacy organizations 35
National association of pharmacists 31
National association of pharmaceutical
research and manufacturing companies 26
Government agency 21
Leading pharmaceutical company like
Merck, Pfizer or Novartis 14
Source: Pfizer, 2004
![Page 43: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/43.jpg)
43
TRUST IN INDUSTRY INFORMATION:UK GPs
4%
2%
5%
5%
6%
19%
21%
22%
34%
39%
47%
55%
63%
65%
68% Doctors
Colleagues
NICE
Prescribing advisors
Pharmacists
Medical media
Internet sources
PCT/ SHA
Pharmaceutical companies
Government organisations
NHS Direct
Nurses
Patient help groups
Consumer media
None of these
Which, if any, of the following sources, do you generally trust to provide helpful and reliable information about medicines? Base: All respondents (200)
DECEMBER (1) 2006OPINIONS OF CERTAIN INDUSTRIES
Source: GfK / ABPI, December 2006
![Page 44: Reinhard Angelmar The Salmon and Rameau Fellow in Healthcare Management Professor of Marketing INSEAD, Fontainebleau, France The International Pharmaceutical](https://reader034.vdocuments.net/reader034/viewer/2022051621/5697bfca1a28abf838ca95b0/html5/thumbnails/44.jpg)
44
CONCLUSIONS• Perception gaps
– Between beliefs and reality – Between industry beliefs and stakeholder beliefs
• Attitudes toward industry– The proportion of persons favorable / unfavorably toward the
industry varies between 4:1 to 2:1 approximately, depending on the surveyed population
– Compared to other industries, the pharmaceutical industry is well regarded in Europe
• Strongest positives associated with the industry: – R&D/innovation– Patient outcomes
• Strongest negatives associated with the industry:– Pricing– Transparency– Sales & marketing practices
• Significant number of persons do not trust the industry
TO CHANGE THE WORLD WE HAVE TO CHANGE OURSELVES